| The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group. | |
| | |
MedLine Citation:
|
PMID: 1520648 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
TIBET is a European multicenter, double-blind parallel group trial with the main objective of investigating whether total ischemic burden has important prognostic implications in patients with stable angina on treatment. A secondary objective is to compare the antianginal and antiischemic effects of atenolol (50 mg bid), nifedipine (20-40 mg bid), and their combination using standardized exercise testing and Holter monitoring techniques. The main primary end points are cardiovascular morbidity and mortality. The secondary end points are time to onset of significant ischemia, angina on exercise stress testing, exercise capacity at onset of angina, 1-mm ST-segment depression and termination of exercise, total duration and number of significant ischemic episodes during 48 hours of Holter monitoring, and their circadian distribution. The target population, the assessments, and the management of the trial are described in detail. |
| | |
Authors:
|
- |
Related Documents
:
|
6363078 - Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced ang... 7124628 - Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hy... 6796288 - The effects of lidoflazine on exercise performance and thallium stress scintigraphy in ... 3930248 - The time of onset of action of sublingual nitroglycerin in exercise-induced angina pect... 19432298 - Effects of acute exercise on atherogenic lipids in untreated mild hypertensive patients. 8774818 - Benefits and limitations of rate adaptive pacing under laboratory and daily life condit... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 6 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 1992 Aug |
Date Detail:
|
Created Date: 1992-10-09 Completed Date: 1992-10-09 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 379-86 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angina Pectoris / complications, drug therapy*, mortality Atenolol / therapeutic use* Coronary Disease / etiology* Data Interpretation, Statistical Double-Blind Method Drug Therapy, Combination Electrocardiography, Ambulatory Exercise Test Female Humans Male Middle Aged Nifedipine / therapeutic use* Prognosis |
| Chemical | |
Reg. No./Substance:
|
21829-25-4/Nifedipine; 29122-68-7/Atenolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency...
Next Document: Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term eff...